BioAge Labs Inc.
Organization details
- Legal name
- BioAge Labs Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Emeryville
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BIOA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001709941
- EIN
- 47-4721157
Board of directors
-
Eric Morgen · Director · Chief Operating OfficerSince 2024
- Since 2024
-
Jean Pierre Garnier · DirectorSince 2024
-
Kristen Fortney · Director · Chief Executive OfficerSince 2024
-
Michael H. Davidson · DirectorSince 2024
- Since 2024
-
Rekha Hemrajani · DirectorSince 2024
-
Vijay Satyanand Pande · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.6%
-
89.0%
-
96.2%
Board connections
6 of this board's directors also sit on 17 other boards. 15 are in the same sector.
-
ALX Oncology Holdings Inc. Same sectorvia Rekha Hemrajani
-
ArriVent BioPharma Inc. Same sectorvia James Healy
-
Bolt Biotherapeutics Inc. Same sectorvia James Healy
- via Jean Pierre Garnier
-
Jazz Pharmaceuticals plc Same sectorvia Patrick G. Enright
-
LB Pharmaceuticals Inc Same sectorvia Rekha Hemrajani
-
MaxCyte Inc. Same sectorvia Rekha Hemrajani
-
Natera Inc. Same sectorvia James Healy
- via Vijay Satyanand Pande
-
NewAmsterdam Pharma Company N.V. Same sectorvia Michael H. Davidson
-
Rapport Therapeutics Inc. Same sectorvia James Healy
-
Seaport Therapeutics Inc. Same sectorvia James Healy
- via Michael H. Davidson
-
Tenax Therapeutics Inc. Same sectorvia Michael H. Davidson
-
Vera Therapeutics Inc. Same sectorvia Patrick G. Enright
-
Veradermics Incorporated Same sectorvia Patrick G. Enright
-
Zenas BioPharma Inc. Same sectorvia Patrick G. Enright
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $7,793,544
- 13 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Barton Shane Officer (Principal Accounting Officer) | Option exercise | +4,290 | $10.85 | $46,547 |
| Jun 30, 2026 | Barton Shane Officer (Principal Accounting Officer) | Option exercise | +4,000 | $8.39 | $33,560 |
| Jun 30, 2026 | Barton Shane Officer (Principal Accounting Officer) | Option exercise | +4,065 | $4.30 | $17,480 |
| Jun 30, 2026 | Barton Shane Officer (Principal Accounting Officer) | Option exercise | +7,861 | $4.38 | $34,431 |
| Jun 30, 2026 | Barton Shane Officer (Principal Accounting Officer) | Open-market sale | −20,216 | $25.19 | $509,241 |
| Jun 29, 2026 | Barton Shane Officer (Principal Accounting Officer) | Option exercise | +9,301 | $10.85 | $100,916 |
| Jun 29, 2026 | Barton Shane Officer (Principal Accounting Officer) | Option exercise | +7,261 | $8.39 | $60,920 |
| Jun 29, 2026 | Barton Shane Officer (Principal Accounting Officer) | Option exercise | +8,958 | $4.30 | $38,519 |
| Jun 29, 2026 | Barton Shane Officer (Principal Accounting Officer) | Option exercise | +14,198 | $4.38 | $62,187 |
| Jun 29, 2026 | Barton Shane Officer (Principal Accounting Officer) | Open-market sale | −42,350 | $25.21 | $1,067,644 |
| Apr 23, 2026 | Dov A. Goldstein M.D. Officer (Chief Financial Officer) | Option exercise | +3,542 | $4.38 | $15,514 |
| Apr 1, 2026 | RUBIN PAUL D Officer (Chief Medical Officer) | Option exercise | +5,437 | $4.11 | $22,346 |
| Apr 1, 2026 | RUBIN PAUL D Officer (Chief Medical Officer) | Option exercise | +3,383 | $6.57 | $22,226 |
| Apr 1, 2026 | RUBIN PAUL D Officer (Chief Medical Officer) | Open-market sale | −8,820 | $17.81 | $157,084 |
| Mar 2, 2026 | RUBIN PAUL D Officer (Chief Medical Officer) | Option exercise | +5,433 | $4.11 | $22,330 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about BioAge Labs Inc.
Who is the CEO of BioAge Labs Inc.?
Kristen Fortney has been BioAge Labs Inc.'s Chief Executive Officer since September 2024.
How many directors are on BioAge Labs Inc.'s board?
BioAge Labs Inc.'s board has 8 directors: Eric Morgen, James Healy, Jean Pierre Garnier, Kristen Fortney, Michael H. Davidson, Patrick G. Enright, Rekha Hemrajani and Vijay Satyanand Pande.
Are BioAge Labs Inc. insiders buying or selling shares?
Over the last 12 months, BioAge Labs Inc. insiders made no open-market purchases and sold $7.8 million of shares in 13 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="bioage-labs-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.